The Journal of Allergy and Clinical Immunology
Volume 111, Issue 1 , Pages 3-22 , January 2003

Update on glucocorticoid action and resistance

Received 23 October 2002 ,Accepted 23 October 2002.

References 

  1. Oettgen HC, Geha RS. IgE regulation and roles in asthma pathogenesis. J Allergy Clin Immunol. 2001;107:429–440
  2. Wills-Karp M. IL-12/IL-13 axis in allergic asthma. J Allergy Clin Immunol. 2001;107:9–18
  3. Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR. Systemic lupus erythematosus. Lancet. 2001;357:1027–1032
  4. Busse WW, Taggart V, Lemanske RF. Asthma guidelines: a changing paradigm to improve asthma care. J Allergy Clin Immunol. 2002;110:703–705
  5. Scadding GK. Corticosteroids in the treatment of pediatric allergic rhinitis. J Allergy Clin Immunol. 2001;108:S59–S64
  6. Francke U, Foellmer BE. The glucocorticoid receptor gene is in 5q31-q32 [published correction appears in Genomics. 1989;5:388]. Genomics. 1989;4:610–612
  7. Encio IJ, Detera-Wadleigh SD. The genomic structure of the human glucocorticoid receptor. J Biol Chem. 1991;266:7182–7188
  8. Breslin MB, Geng CD, Vedeckis WV. Multiple promoters exist in the human GR gene, one of which is activated by glucocorticoids. Mol Endocrinol. 2001;15:1381–1395
  9. Bamberger CM, Bamberger AM, de Castro M, Chrousos GP. Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest. 1995;95:2435–2441
  10. Oakley RH, Webster JC, Sar M, Parker CR, Cidlowski JA. Expression and subcellular distribution of the beta-isoform of the human glucocorticoid receptor. Endocrinology. 1997;138:5028–5038
  11. Oakley RH, Sar M, Cidlowski JA. The human glucocorticoid receptor beta isoform. Expression, biochemical properties, and putative function. J Biol Chem. 1996;271:9550–9559
  12. de Castro M, Elliot S, Kino T, Bamberger C, Karl M, Webster E, et al.  The non-ligand binding beta-isoform of the human glucocorticoid receptor (hGR beta): tissue levels, mechanism of action, and potential physiologic role. Mol Med. 1996;2:597–607
  13. Bloom JW, Miesfeld RL. Molecular mechanisms of glucocorticoid action. In:  Szefler SJ,  Leung DYM editor. Severe asthma: pathogenesis and clinical management. New York: Marcel Dekker; 1996;p. 255
  14. Bledsoe RK, Montana VG, Stanley TB, Delves CJ, Apolito CJ, McKee DD, et al.  Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell. 2002;110:93–105
  15. Savory JG, Hsu B, Laquian IR, Giffin W, Reich T, Hache RJ, et al.  Discrimination between NL1- and NL2-mediated nuclear localization of the glucocorticoid receptor. Mol Cell Biol. 1999;19:1025–1037
  16. Hache RJ, Tse R, Reich T, Savory JG, Lefebvre YA. Nucleocytoplasmic trafficking of steroid-free glucocorticoid receptor. J Biol Chem. 1999;274:1432–1439
  17. Torchia J, Glass C, Rosenfeld MG. Co-activators and co-repressors in the integration of transcriptional responses. Curr Opin Cell Biol. 1998;10:373–383
  18. Darimont BD, Wagner RL, Apriletti JW, Stallcup MR, Kushner PJ, Baxter JD, et al.  Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev. 1998;12:3343–3356
  19. Freedman LP. Anatomy of the steroid receptor zinc finger region. Endocr Rev. 1992;13:129–145
  20. Hollenberg SM, Evans RM. Multiple and cooperative trans-activation domains of the human glucocorticoid receptor. Cell. 1988;55:899–906
  21. Ford J, McEwan IJ, Wright AP, Gustafsson JA. Involvement of the transcription factor IID protein complex in gene activation by the N-terminal transactivation domain of the glucocorticoid receptor in vitro. Mol Endocrinol. 1997;11:1467–1475
  22. Kino T, Chrousos GP. Tissue-specific glucocorticoid resistance-hypersensitivity syndromes: multifactorial states of clinical importance. J Allergy Clin Immunol. 2002;109:609–613
  23. Iniguez-Lluhi JA, Lou DY, Yamamoto KR. Three amino acid substitutions selectively disrupt the activation but not the repression function of the glucocorticoid receptor N terminus. J Biol Chem. 1997;272:4149–4156
  24. Cheung J, Smith DF. Molecular chaperone interactions with steroid receptors: an update. Mol Endocrinol. 2000;14:939–946
  25. Featherstone M. Coactivators in transcription initiation: here are your orders. Curr Opin Genet Dev. 2002;12:149–155
  26. Chan HM, La Thangue NB. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci. 2001;114:2363–2373
  27. Jenster G. Coactivators and corepressors as mediators of nuclear receptor function: an update. Mol Cell Endocrinol. 1998;143:1–7
  28. Onate SA, Tsai SY, Tsai MJ, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science. 1995;270:1354–1357
  29. Le Douarin B, Nielsen AL, Garnier JM, Ichinose H, Jeanmougin F, Losson R, et al.  A possible involvement of TIF1 alpha and TIF1 beta in the epigenetic control of transcription by nuclear receptors. EMBO J. 1996;15:6701–6715
  30. Hong H, Darimont BD, Ma H, Yang L, Yamamoto KR, Stallcup MR. An additional region of coactivator GRIP1 required for interaction with the hormone-binding domains of a subset of nuclear receptors. J Biol Chem. 1999;274:3496–3502
  31. Hong H, Kohli K, Garabedian MJ, Stallcup MR. GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors. Mol Cell Biol. 1997;17:2735–2744
  32. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 1998;12:599–606
  33. Allfrey V, Faulkner RM, Mirsky AE. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc Natl Acad Sci U S A. 1964;51:786–794
  34. Kornberg RD, Lorch Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell. 1999;98:285–294
  35. Struhl K, Moqtaderi Z. The TAFs in the HAT. Cell. 1998;94:1–4
  36. Tyler JK, Kadonaga JT. The “dark side” of chromatin remodeling: repressive effects on transcription. Cell. 1999;99:443–446
  37. Agarwal S, Viola JP, Rao A. Chromatin-based regulatory mechanisms governing cytokine gene transcription. J Allergy Clin Immunol. 1999;103:990–999
  38. Ito K, Barnes PJ, Adcock IM. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol. 2000;20:6891–6903
  39. Ito K, Caramori G, Lim S, Oates T, Chung KF, Barnes PJ, et al.  Expression and activity of histone deacetylases in human asthmatic airways. Am J Respir Crit Care Med. 2002;166:392–396
  40. Vignali M, Hassan AH, Neely KE, Workman JL. ATP-dependent chromatin-remodeling complexes. Mol Cell Biol. 2000;20:1899–1910
  41. Fryer CJ, Archer TK. Chromatin remodelling by the glucocorticoid receptor requires the BRG1 complex. Nature. 1998;393:88–91
  42. McNally JG, Muller WG, Walker D, Wolford R, Hager GL. The glucocorticoid receptor: rapid exchange with regulatory sites in living cells. Science. 2000;287:1262–1265
  43. Freeman BC, Yamamoto KR. Disassembly of transcriptional regulatory complexes by molecular chaperones. Science. 2002;296:2232–2235
  44. Fletcher TM, Xiao N, Mautino G, Baumann CT, Wolford R, Warren BS, et al.  ATP-dependent mobilization of the glucocorticoid receptor during chromatin remodeling. Mol Cell Biol. 2002;22:3255–3263
  45. DeFranco DB. Navigating steroid hormone receptors through the nuclear compartment. Mol Endocrinol. 2002;16:1449–1455
  46. Cella N, Groner B, Hynes NE. Characterization of Stat5a and Stat5b homodimers and heterodimers and their association with the glucocortiocoid receptor in mammary cells. Mol Cell Biol. 1998;18:1783–1792
  47. Doppler W, Windegger M, Soratroi C, Tomasi J, Lechner J, Rusconi S, et al.  Expression level-dependent contribution of glucocorticoid receptor domains for functional interaction with STAT5. Mol Cell Biol. 2001;21:3266–3279
  48. Pfitzner E, Jahne R, Wissler M, Stoecklin E, Groner B. p300/CREB-binding protein enhances the prolactin-mediated transcriptional induction through direct interaction with the transactivation domain of Stat5, but does not participate in the Stat5-mediated suppression of the glucocorticoid response. Mol Endocrinol. 1998;12:1582–1593
  49. Zhang Z, Jones S, Hagood JS, Fuentes NL, Fuller GM. STAT3 acts as a co-activator of glucocorticoid receptor signaling. J Biol Chem. 1997;272:30607–30610
  50. Prefontaine GG, Walther R, Giffin W, Lemieux ME, Pope L, Hache RJ. Selective binding of steroid hormone receptors to octamer transcription factors determines transcriptional synergism at the mouse mammary tumor virus promoter. J Biol Chem. 1999;274:26713–26719
  51. Cram EJ, Ramos RA, Wang EC, Cha HH, Nishio Y, Firestone GL. Role of the CCAAT/enhancer binding protein-alpha transcription factor in the glucocorticoid stimulation of p21waf1/cip1 gene promoter activity in growth-arrested rat hepatoma cells. J Biol Chem. 1998;273:2008–2014
  52. Mullick J, Anandatheerthavarada HK, Amuthan G, Bhagwat SV, Biswas G, Camasamudram V, et al.  Physical interaction and functional synergy between glucocorticoid receptor and Ets2 proteins for transcription activation of the rat cytochrome P-450c27 promoter. J Biol Chem. 2001;276:18007–18017
  53. Bodwell JE, Webster JC, Jewell CM, Cidlowski JA, Hu JM, Munck A. Glucocorticoid receptor phosphorylation: overview, function and cell cycle-dependence. J Steroid Biochem Mol Biol. 1998;65:91–99
  54. Wang Z, Frederick J, Garabedian MJ. Deciphering the phosphorylation “code” of the glucocorticoid receptor in vivo. J Biol Chem. 2002;277:26573–26580
  55. Krstic MD, Rogatsky I, Yamamoto KR, Garabedian MJ. Mitogen-activated and cyclin-dependent protein kinases selectively and differentially modulate transcriptional enhancement by the glucocorticoid receptor. Mol Cell Biol. 1997;17:3947–3954
  56. Rogatsky I, Logan SK, Garabedian MJ. Antagonism of glucocorticoid receptor transcriptional activation by the c-Jun N-terminal kinase. Proc Natl Acad Sci U S A. 1998;95:2050–2055
  57. Itoh M, Adachi M, Yasui H, Takekawa M, Tanaka H, Imai K. Nuclear export of glucocorticoid receptor is enhanced by c-Jun N-terminal kinase-mediated phosphorylation. Mol Endocrinol. 2002;16:2382–2392
  58. Flower RJ. Eleventh Gaddum memorial lecture. Lipocortin and the mechanism of action of the glucocorticoids. Br J Pharmacol. 1988;94:987–1015
  59. Re F, Muzio M, De Rossi M, Polentarutti N, Giri JG, Mantovani A, et al.  The type II “receptor” as a decoy target for interleukin 1 in polymorphonuclear leukocytes: characterization of induction by dexa-methasone and ligand binding properties of the released decoy receptor. J Exp Med. 1994;179:739–743
  60. Sallenave JM, Shulmann J, Crossley J, Jordana M, Gauldie J. Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am J Respir Cell Mol Biol. 1994;11:733–741
  61. Mulligan MS, Lentsch AB, Huber-Lang M, Guo RF, Sarma V, Wright CD, et al.  Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor. Am J Pathol. 2000;156:1033–1039
  62. Umland SP, Schleimer RP, Johnston SL. Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm Pharmacol Ther. 2002;15:35–50
  63. Atsuta J, Plitt J, Bochner BS, Schleimer RP. Inhibition of VCAM-1 expression in human bronchial epithelial cells by glucocorticoids. Am J Respir Cell Mol Biol. 1999;20:643–650
  64. van de Stolpe A, Caldenhoven E, Raaijmakers JA, van der Saag PT, Koenderman L. Glucocorticoid-mediated repression of intercellular adhesion molecule-1 expression in human monocytic and bronchial epithelial cell lines. Am J Respir Cell Mol Biol. 1993;8:340–347
  65. Gosset P, Lamblin-Degros C, Tillie-Leblond I, Charbonnier AS, Joseph M, Wallaert B, et al.  Modulation of high-affinity IgE receptor expression in blood monocytes: opposite effect of IL-4 and glucocorticoids. J Allergy Clin Immunol. 2001;107:114–122
  66. Mozo L, Gayo A, Suarez A, Rivas D, Zamorano J, Gutierrez C. Glucocorticoids inhibit IL-4 and mitogen-induced IL-4R alpha chain expression by different posttranscriptional mechanisms. J Allergy Clin Immunol. 1998;102:968–976
  67. Mitchell JA, Belvisi MG, Akarasereenont P, Robbins RA, Kwon OJ, Croxtall J, et al.  Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone. Br J Pharmacol. 1994;113:1008–1014
  68. Singer M, Lefort J, Vargaftig BB. Granulocyte depletion and dexa-methasone differentially modulate airways hyperreactivity, inflammation, mucus accumulation, and secretion induced by rmIL-13 or antigen. Am J Respir Cell Mol Biol. 2002;26:74–84
  69. Ristimaki A, Narko K, Hla T. Down-regulation of cytokine-induced cyclo-oxygenase-2 transcript isoforms by dexamethasone: evidence for post-transcriptional regulation. Biochem J. 1996;318:325–331
  70. Bickel M, Iwai Y, Pluznik DH, Cohen RB. Binding of sequence-specific proteins to the adenosine- plus uridine-rich sequences of the murine granulocyte/macrophage colony-stimulating factor mRNA. Proc Natl Acad Sci U S A. 1992;89:10001–10005
  71. Adkins KK, Levan TD, Miesfeld RL, Bloom JW. Glucocorticoid regulation of GM-CSF: evidence for transcriptional mechanisms in airway epithelial cells. Am J Physiol. 1998;275:L372–L378
  72. Newton R, Seybold J, Kuitert LM, Bergmann M, Barnes PJ. Repression of cyclooxygenase-2 and prostaglandin E2 release by dexamethasone occurs by transcriptional and post-transcriptional mechanisms involving loss of polyadenylated mRNA. J Biol Chem. 1998;273:32312–32321
  73. Wang J, Zhu Z, Nolfo R, Elias JA. Dexamethasone regulation of lung epithelial cell and fibroblast interleukin-11 production. Am J Physiol. 1999;276:L175–L185
  74. Adcock IM. Molecular mechanisms of glucocorticosteroid actions. Pulm Pharmacol Ther. 2000;13:115–126
  75. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066–1071
  76. Drouin J, Sun YL, Chamberland M, Gauthier Y, De Lean A, Nemer M, et al.  Novel glucocorticoid receptor complex with DNA element of the hormone-repressed POMC gene. EMBO J. 1993;12:145–156
  77. Meyer T, Carlstedt-Duke J, Starr DB. A weak TATA box is a prerequisite for glucocorticoid-dependent repression of the osteocalcin gene. J Biol Chem. 1997;272:30709–30714
  78. Miner JN, Yamamoto KR. The basic region of AP-1 specifies glucocorticoid receptor activity at a composite response element. Genes Dev. 1992;6:2491–2501
  79. Schule R, Rangarajan P, Kliewer S, Ransone LJ, Bolado J, Yang N, et al.  Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell. 1990;62:1217–1226
  80. Yang-Yen HF, Chambard JC, Sun YL, Smeal T, Schmidt TJ, Drouin J, et al.  Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell. 1990;62:1205–1215
  81. Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, Bock R, et al.  DNA binding of the glucocorticoid receptor is not essential for survival. Cell. 1998;93:531–541
  82. Heck S, Kullmann M, Gast A, Ponta H, Rahmsdorf HJ, Herrlich P, et al.  A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. EMBO J. 1994;13:4087–4095
  83. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol. 1994;10:405–455
  84. Baldwin AS. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649–683
  85. Caldenhoven E, Liden J, Wissink S, Van de Stolpe A, Raaijmakers J, Koenderman L, et al.  Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids. Mol Endocrinol. 1995;9:401–412
  86. Nissen RM, Yamamoto KR. The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev. 2000;14:2314–2329
  87. De Bosscher K, Vanden Berghe W, Vermeulen L, Plaisance S, Boone E, Haegeman G. Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc Natl Acad Sci U S A. 2000;97:3919–3924
  88. Ito K, Jazrawi E, Cosio B, Barnes PJ, Adcock IM. p65-activated histone acetyltransferase activity is repressed by glucocorticoids: mifepristone fails to recruit HDAC2 to the p65-HAT complex. J Biol Chem. 2001;276:30208–30215
  89. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995;270:286–290
  90. Brostjan C, Anrather J, Csizmadia V, Stroka D, Soares M, Bach FH, et al.  Glucocorticoid-mediated repression of NFkappaB activity in endothelial cells does not involve induction of IkappaBalpha synthesis. J Biol Chem. 1996;271:19612–19616
  91. Adcock IM, Nasuhara Y, Stevens DA, Barnes PJ. Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF-kappaB and lack of I-kappaB involvement. Br J Pharmacol. 1999;127:1003–1011
  92. Reichardt HM, Tuckermann JP, Gottlicher M, Vujic M, Weih F, Angel P, et al.  Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J. 2001;20:7168–7173
  93. Sher ER, Leung DY, Surs W, Kam JC, Zieg G, Kamada AK, et al.  Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest. 1994;93:33–39
  94. Chan MT, Leung DY, Szefler SJ, Spahn JD. Difficult-to-control asthma: clinical characteristics of steroid-insensitive asthma. J Allergy Clin Immunol. 1998;101:594–601
  95. Szefler SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM, et al.  Significant variability in response to inhaled cortico-steroids for persistent asthma. J Allergy Clin Immunol. 2002;109:410–418
  96. van Schaardenburg D, Valkema R, Dijkmans BA, Papapoulos S, Zwinderman AH, Han KH, et al.  Prednisone treatment of elderly-onset rheumatoid arthritis. Disease activity and bone mass in comparison with chloroquine treatment. Arthritis Rheum. 1995;38:334–342
  97. Seki M, Ushiyama C, Seta N, Abe K, Fukazawa T, Asakawa J, et al.  Apoptosis of lymphocytes induced by glucocorticoids and relationship to therapeutic efficacy in patients with systemic lupus erythematosus. Arthritis Rheum. 1998;41:823–830
  98. Hearing SD, Norman M, Probert CS, Haslam N, Dayan CM. Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut. 1999;45:382–388
  99. Honda M, Orii F, Ayabe T, Imai S, Ashida T, Obara T, et al.  Expression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology. 2000;118:859–866
  100. Hamilos DL. Chronic sinusitis. J Allergy Clin Immunol. 2000;106:213–227
  101. Noh G, Lee KY. Intravenous immune globulin (i.v.IG) therapy in steroid-resistant atopic dermatitis. J Korean Med Sci. 1999;14:63–68
  102. Hearing SD, Norman M, Smyth C, Foy C, Dayan CM. Wide variation in lymphocyte steroid sensitivity among healthy human volunteers. J Clin Endocrinol Metab. 1999;84:4149–4154
  103. Corrigan CJ, Brown PH, Barnes NC, Szefler SJ, Tsai JJ, Frew AJ, et al.  Glucocorticoid resistance in chronic asthma. Glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro. Am Rev Respir Dis. 1991;144:1016–1025
  104. Alvarez J, Surs W, Leung DY, Iklé D, Gelfand EW, Szefler SJ. Steroid-resistant asthma: immunologic and pharmacologic features. J Allergy Clin Immunol. 1992;89:714–721
  105. Corrigan CJ, Brown PH, Barnes NC, Tsai JJ, Frew AJ, Kay AB. Glucocorticoid resistance in chronic asthma. Peripheral blood T lymphocyte activation and comparison of the T lymphocyte inhibitory effects of glucocorticoids and cyclosporin A. Am Rev Respir Dis. 1991;144:1026–1032
  106. Hawrylowicz C, Richards D, Loke TK, Corrigan C, Lee T. A defect in corticosteroid-induced IL-10 production in T lymphocytes from corticosteroid-resistant asthmatic patients. J Allergy Clin Immunol. 2002;109:369–370
  107. Spahn JD, Landwehr LP, Nimmagadda S, Surs W, Leung DY, Szefler SJ. Effects of glucocorticoids on lymphocyte activation in patients with steroid-sensitive and steroid-resistant asthma. J Allergy Clin Immunol. 1996;98:1073–1079
  108. Leung DY, Martin RJ, Szefler SJ, Sher ER, Ying S, Kay AB, et al.  Dysregulation of interleukin 4, interleukin 5, and interferon gamma gene expression in steroid-resistant asthma. J Exp Med. 1995;181:33–40
  109. Chrousos GP, Detera-Wadleigh SD, Karl M. Syndromes of glucocorticoid resistance. Ann Intern Med. 1993;119:1113–1124
  110. Lane SJ, Arm JP, Staynov DZ, Lee TH. Chemical mutational analysis of the human glucocorticoid receptor cDNA in glucocorticoid-resistant bronchial asthma. Am J Respir Cell Mol Biol. 1994;11:42–48
  111. Kam JC, Szefler SJ, Surs W, Sher ER, Leung DY. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J Immunol. 1993;151:3460–3466
  112. Spahn JD, Szefler SJ, Surs W, Doherty DE, Nimmagadda SR, Leung DY. A novel action of IL-13: induction of diminished monocyte glucocorticoid receptor-binding affinity. J Immunol. 1996;157:2654–2659
  113. Adcock IM, Lane SJ, Brown CR, Lee TH, Barnes PJ. Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma. J Exp Med. 1995;182:1951–1958
  114. Lane SJ, Adcock IM, Richards D, Hawrylowicz C, Barnes PJ, Lee TH. Corticosteroid-resistant bronchial asthma is associated with increased c-fos expression in monocytes and T lymphocytes. J Clin Invest. 1998;102:2156–2164
  115. Sousa AR, Lane SJ, Soh C, Lee TH. In vivo resistance to cortico-steroids in bronchial asthma is associated with enhanced phosyphorylation of JUN N-terminal kinase and failure of prednisolone to inhibit JUN N-terminal kinase phosphorylation. J Allergy Clin Immunol. 1999;104:565–574
  116. Irusen E, Matthews JG, Takahashi A, Barnes PJ, Chung KF, Adcock IM. p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol. 2002;109:649–657
  117. Loke TK, Sousa AR, Corrigan CJ, Lee TH. Glucocorticoid-resistant asthma. Curr Allergy Asthma Rep. 2002;2:144–150
  118. Goleva E, Kisich KO, Leung DYM. Stat 5. A role for STAT5 in the pathogenesis of IL-2 induced glucocorticoid resistance. J Immunol. 2002;169:5934–5940
  119. Oakley RH, Jewell CM, Yudt MR, Bofetiado DM, Cidlowski JA. The dominant negative activity of the human glucocorticoid receptor beta isoform. Specificity and mechanisms of action. J Biol Chem. 1999;274:27857–27866
  120. Hauk PJ, Goleva E, Strickland I, Vottero A, Chrousos GP, Kisich KO, et al.  Increased glucocorticoid receptor Beta expression converts mouse hybridoma cells to a corticosteroid-insensitive phenotype. Am J Respir Cell Mol Biol. 2002;27:361–367
  121. Strickland I, Kisich K, Hauk PJ, Vottero A, Chrousos GP, Klemm DJ, et al.  High constitutive glucocorticoid receptor beta in human neutrophils enables them to reduce their spontaneous rate of cell death in response to corticosteroids. J Exp Med. 2001;193:585–594
  122. Leung DY, Hamid Q, Vottero A, Szefler SJ, Surs W, Minshall E, et al.  Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta. J Exp Med. 1997;186:1567–1574
  123. Webster JC, Oakley RH, Jewell CM, Cidlowski JA. Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: a mechanism for the generation of glucocorticoid resistance. Proc Natl Acad Sci U S A. 2001;98:6865–6870
  124. Xu Q, Kisich KO, Strickland I, Lewis MT, Leung DYM. Increased expression of SR protein P30 in neutrophils [abstract 338]. J Allergy Clin Immunol. 2002;109:S119
  125. Hamid QA, Wenzel SE, Hauk PJ, Tsicopoulos A, Wallaert B, Lafitte JJ, et al.  Increased glucocorticoid receptor beta in airway cells of glucocorticoid-insensitive asthma. Am J Respir Crit Care Med. 1999;159:1600–1604
  126. Vottero A, Chrousos GP. Glucocorticoid Receptor beta: view I. Trends Endocrinol Metab. 1999;10:333–338
  127. Otto C, Reichardt HM, Schutz G. Absence of glucocorticoid receptor-beta in mice. J Biol Chem. 1997;272:26665–26668
  128. Sousa AR, Lane SJ, Cidlowski JA, Staynov DZ, Lee TH. Glucocorticoid resistance in asthma is associated with elevated in vivo expression of the glucocorticoid receptor beta-isoform. J Allergy Clin Immunol. 2000;105:943–950
  129. Christodoulopoulos P, Leung DY, Elliott MW, Hogg JC, Muro S, Toda M, et al.  Increased number of glucocorticoid receptor-beta-expressing cells in the airways in fatal asthma. J Allergy Clin Immunol. 2000;106:479–484
  130. Kraft M, Vianna E, Martin RJ, Leung DY. Nocturnal asthma is associated with reduced glucocorticoid receptor binding affinity and decreased steroid responsiveness at night. J Allergy Clin Immunol. 1999;103:66–71
  131. Kraft M, Hamid Q, Chrousos GP, Martin RJ, Leung DY. Decreased steroid responsiveness at night in nocturnal asthma. Is the macrophage responsible?. Am J Respir Crit Care Med. 2001;163:1219–1225
  132. Hamilos DL, Leung DY, Muro S, Kahn AM, Hamilos SS, Thawley SE, et al.  GRbeta expression in nasal polyp inflammatory cells and its relationship to the anti-inflammatory effects of intranasal fluticasone. J Allergy Clin Immunol. 2001;108:59–68
  133. Burchard EG, Silverman EK, Rosenwasser LJ, Borish L, Yandava C, Pillari A, et al.  Association between a sequence variant in the IL-4 gene promoter and FEV(1) in asthma. Am J Respir Crit Care Med. 1999;160:919–922
  134. Rosa-Rosa L, Zimmermann N, Bernstein JA, Rothenberg ME, Khurana Hershey GK. The R576 IL-4 receptor alpha allele correlates with asthma severity. J Allergy Clin Immunol. 1999;104:1008–1014
  135. Rosenwasser L, Klemm JD, Klemm DJ, Drazen JM, Burchard EG, Leung DYM. Association of asthmatic steroid insensitivity with an Il-4 gene promoter polymorphism [abstract 771]. J Allergy Clin Immunol. 2001;107:S235
  136. Spahn JD, Brown EE, Covar R, Leung DYM. Do African-Americans display a diminished response to GCs (GCs)? [abstract]. J Allergy Clin Immunol. 1999;103:S62
  137. Nimmagadda SR, Szefler SJ, Spahn JD, Surs W, Leung DY. Allergen exposure decreases glucocorticoid receptor binding affinity and steroid responsiveness in atopic asthmatics. Am J Respir Crit Care Med. 1997;155:87–93
  138. Hauk PJ, Wenzel SE, Trumble AE, Szefler SJ, Leung DY. Increased T-cell receptor vbeta8+ T cells in bronchoalveolar lavage fluid of subjects with poorly controlled asthma: a potential role for microbial superantigens. J Allergy Clin Immunol. 1999;104:37–45
  139. Kotzin BL, Leung DY, Kappler J, Marrack P. Superantigens and their potential role in human disease. Adv Immunol. 1993;54:99–166
  140. Hauk PJ, Hamid QA, Chrousos GP, Leung DY. Induction of corticosteroid insensitivity in human PBMCs by microbial superantigens. J Allergy Clin Immunol. 2000;105:782–787
  141. Bunikowski R, Mielke ME, Skarabis H, Worm M, Anagnostopoulos I, Kolde G, et al.  Evidence for a disease-promoting effect of Staphylococcus aureus -derived exotoxins in atopic dermatitis. J Allergy Clin Immunol. 2000;105:814–819
  142. Nomura I, Tanaka K, Tomita H, Katsunuma T, Ohya Y, Ikeda N, et al.  Evaluation of the staphylococcal exotoxins and their specific IgE in childhood atopic dermatitis. J Allergy Clin Immunol. 1999;104:441–446
  143. Wenzel SE, Szefler SJ, Leung DY, Sloan SI, Rex MD, Martin RJ. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med. 1997;156:737–743
  144. Herrscher RF, Kasper C, Sullivan TJ. Endogenous cortisol regulates immunoglobulin E-dependent late phase reactions. J Clin Invest. 1992;90:596–603
  145. Leung DYM, Spahn JD, Szefler SJ. Steroid-resistant asthma: new insights and implications for management. In: 2nd ed.  Szefler SJ,  Leung DYM editor. Severe asthma: a multidisciplinary approach. New York: Marcel Dekker, Inc; 2001;p. 597–620
  146. Murray AB, Ferguson AC, Morrison BJ. The frequency and severity of cat allergy vs. dog allergy in atopic children. J Allergy Clin Immunol. 1983;72:145–149
  147. Perzanowski MS, Ronmark E, Nold B, Lundback B, Platts-Mills TA. Relevance of allergens from cats and dogs to asthma in the northernmost province of Sweden: schools as a major site of exposure. J Allergy Clin Immunol. 1999;103:1018–1024
  148. Bender BG. Overcoming barriers to nonadherence in asthma treatment. J Allergy Clin Immunol. 2002;109:S554–S559
  149. Kraft M, Cassell GH, Henson JE, Watson H, Williamson J, Marmion BP, et al.  Detection of Mycoplasma pneumoniae in the airways of adults with chronic asthma. Am J Respir Crit Care Med. 1998;158:998–1001
  150. Martin RJ, Kraft M, Chu HW, Berns EA, Cassell GH. A link between chronic asthma and chronic infection. J Allergy Clin Immunol. 2001;107:595–601
  151. Leung DYM. Role of Staphylococcus aureus in atopic dermatitis. In:  Bieber T,  Leung DYM editor. Atopic dermatitis. New York: Marcel Dekker, Inc; 2002;p. 401–418
  152. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ. 2000;320:1368–1373
  153. Nelson HS. Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma. J Allergy Clin Immunol. 2001;107:398–416
  154. Eickelberg O, Roth M, Lorx R, Bruce V, Rudiger J, Johnson M, et al.  Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem. 1999;274:1005–1010
  155. Tamaoki J, Kondo M, Sakai N, Nakata J, Takemura H, Nagai A, et al.  Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group Am J Respir Crit Care Med. 1997;155:1235–1240
  156. Nassif EG, Weinberger M, Thompson R, Huntley W. The value of maintenance theophylline in steroid-dependent asthma. N Engl J Med. 1981;304:71–75
  157. Hill MR, Szefler SJ, Ball BD, Bartoszek M, Brenner AM. Monitoring glucocorticoid therapy: a pharmacokinetic approach. Clin Pharmacol Ther. 1990;48:390–398
  158. Kamada AK, Spahn JD, Surs W, Brown E, Leung DY, Szefler SJ. Coexistence of glucocorticoid receptor and pharmacokinetic abnormalities: factors that contribute to a poor response to treatment with glucocorticoids in children with asthma. J Pediatr. 1994;124:984–986
  159. Silkoff PE, Robbins RA, Gaston B, Lundberg JO, Townley RG. Endogenous nitric oxide in allergic airway disease. J Allergy Clin Immunol. 2000;105:438–448
  160. Frew AJ, Plummeridge MJ. Alternative agents in asthma. J Allergy Clin Immunol. 2001;108:3–10
  161. Spahn JD, Leung DY, Chan MT, Szefler SJ, Gelfand EW. Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin. J Allergy Clin Immunol. 1999;103:421–426
  162. Redington AE, Harding FM, Madden J, Holgate ST, Howarth PH. Cyclosporin A treatment and airways inflammation in corticosteroid-dependent asthma. Allergy. 1998;53:94–98
  163. Vrugt B, Wilson S, Bron A, Shute J, Holgate ST, Djukanovic R, et al.  Low-dose methotrexate treatment in severe glucocorticoid-dependent asthma: effect on mucosal inflammation and in vitro sensitivity to glucocorticoids of mitogen-induced T-cell proliferation. Eur Respir J. 2000;15:478–485
  164. Vrugt B, Wilson S, van Velzen E, Bron A, Shute JK, Holgate ST, et al.  Effects of high dose intravenous immunoglobulin in two severe corticosteroid insensitive asthmatic patients. Thorax. 1997;52:662–664
  165. Busse WW, Banks-Schlegel S, Wenzel SE. Pathophysiology of severe asthma. J Allergy Clin Immunol. 2000;106:1033–1042
  166. Molet S, Hamid QA. Role of airway remodeling in severe asthma. In:  Szefler SJ,  Leung DYM editor. Severe asthma: pathogenesis and clinical management. New York: Marcel Dekker, Inc; 2001;p. 89–124
  167. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, et al.  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108:184–190
  168. Broide DH. Molecular and cellular mechanisms of allergic disease. J Allergy Clin Immunol. 2001;108:S65–S71
  169. Wamboldt FS, Spahn JD, Klinnert MD, Wamboldt MZ, Gavin LA, Szefler SJ, et al.  Clinical outcomes of steroid insensitive asthma. Ann Allergy Asthma Immunol. 1999;83:55–60
  170. Ledford D, Apter A, Brenner AM, Rubin K, Prestwood K, Frieri M, et al.  Osteoporosis in the corticosteroid-treated patient with asthma. J Allergy Clin Immunol. 1998;102:353–362
  171. Covar RA, Leung DY, McCormick D, Steelman J, Zeitler P, Spahn JD. Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma. J Allergy Clin Immunol. 2000;106:651–659
  172. Spahn JD, Szefler SJ. Childhood asthma: new insights into management. J Allergy Clin Immunol. 2002;109:3–13

☆ Reprint requests: Donald Y. M. Leung, MD, PhD, National Jewish Medical and Research Center, 1400 Jackson St, Room K926, Denver, CO 80206.

PII: S0091-6749(02)91359-X

doi: 10.1067/mai.2003.97

The Journal of Allergy and Clinical Immunology
Volume 111, Issue 1 , Pages 3-22 , January 2003

Article Tools

* Image Usage & Resolution